This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
WASHINGTON — President Biden is using a Cold War-era law to stem drug shortages by boosting domestic pharmaceuticalmanufacturing. The White House will spend $35 million to boost domestic production of key starting materials for sterile injectables, which are the drugs that hospitals commonly use and are most prone to shortages.
Bringing together over 225+ exhibitors and showcasing 12000+ products and solutions, the expo will represent diverse industries, including pharmaceuticalmanufacturing, biotechnology, medical devices and diagnostics, cosmeceuticals, nutraceuticals, packaging solutions, and healthcare IT.
A marketplace for innovation and growth With a comprehensive array of exhibitors, CPHI & PMEC India enables direct engagement with pharmaceutical executives, buyers, hospital administrators, and government representatives.
Maximizing pharmacys role in your hospitals revenue cycle The 340B landscape continues to evolve rapidly, with ongoing manufacturer restrictions, new compliance hurdles, and increasing financial pressures on covered entities. Recent estimates indicate that hospitals and clinics collectively lose around $3.2
According to ICMR, infections that were once easily treatable are now becoming resistant to widely used antibiotics, leading to prolonged hospital stays, higher mortality rates, and rising healthcare costs. Most of these drugs fail to address emerging bacterial mechanisms, exacerbating the crisis.
It is designed to manufacture a broad range of injectable medications and will provide hospitals and clinicians access to affordable, safe, and critical-need medicines. Nexus Pharmaceuticals President and CEO Usman Ahmed said: “We are thrilled to receive the EIR for our Pleasant Prairie facility.
The Food and Drug Administration (FDA) has successfully inspected Nexus Pharmaceuticals’ pharmaceuticalmanufacturing facility located in Pleasant Prairie, Wisconsin, US. The inspection will allow the company to commence commercial operations at the three-storey, 84,000ft² manufacturing facility.
Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceuticalmanufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.
There have been persistent concerns about AMR being aggravated by effluents from pharmaceuticalmanufacturing plants. Some studies suggest that the concentrations of antibiotics from this pharmaceutical pollution can be up to 1000 times higher than in hospital effluents or municipal sewage.
Pharmaceuticalmanufacturing Oligonucleotides Last month, the Centre for Process Innovation (CPI) announced a new Scotland-based manufacturing facility focusing on oligonucleotide therapeutics. Data showed a 2.5-fold ZUMA-7 is the first and largest Phase III study of any CAR T-cell therapy, with the longest follow-up.
contains new data on hospital acquisitions and consolidation activity. examines how the Inflation Reduction Act could ultimately impact pharmaceutical wholesalers’ customers and business outlook. The notable new material in this 2022-23 edition includes three new sections: Section 3.4.1. Section 6.1.6.
Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceuticalmanufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, lawyers, consultants, and more.
She attributed this to a lack of understanding of the burden of AMR, in part because many patient’s families may not know their loved one died due to an AMR related hospital infection picked up in the hospital during some other procedure. What are the causes of AMR and how is the pharmaceutical industry implicated?
Nobody’s ever put it better than the Association of American Medical Colleges (AAMC): “Congress created the 340B Drug Pricing Program in 1992 to protect safety-net hospitals from escalating drug prices by allowing them to purchase outpatient drugs at a discount from manufacturers. Why are they called Safety Net Hospitals?
This provides an opportunity to directly engage with high-ranking pharma executives, buyers, procurement managers, contract manufacturers, hospital administrators, as well as representatives from national and state regulatory boards and policymakers.
You'll meet an impressive diversity of people from pharmacies, manufacturers, health plans, wholesalers, hospital systems, pharmacy benefit managers, patient advocacy groups, and more. This is a must-attend event for anyone connected to specialty pharmacy. Click here to view the agenda.
The pharmaceutical supply chain is a global and complex network that includes a wide range of stakeholders such as pharmaceuticalmanufacturers, wholesale distributors, and pharmacy benefit managers (PBM), to ensure efficient and timely delivery of medications to the patients.
The Fund – set up as a public-private partnership by the International Federation of PharmaceuticalManufacturers and Associations (IFPMA) – started life with $1 billion earmarked to support companies trying to develop antibiotics that can be used to replace those that have started to lose their effectiveness. ” said Skinner.
He mentions that OPPI member companies follow the stringent OPPI Code of Pharmaceutical Practices 2019 (OPPI Code) which is based on the International Federation of PharmaceuticalManufacturers and Associations (IFPMA) Code. Similarly, section 8.2 ’ Aisola points out that this is a loophole that is widely utilised.
Why specialized software is essential for successful 340B programs As we’ve mentioned in several previous posts, many hospitals taking full advantage of 340B programs’ discounts save millions of dollars a year on prescription costs. We communicate with manufacturers, 340B ESP and wholesalers on behalf of all those 340B programs.
[pharmaceutical companies] must take measures to manage antibiotic waste across the manufacturing supply chain” 2023 has so far, delivered a spectrum of change for antibiotic manufacturers across the pharmaceutical industry, from supply chain issues through to regulatory opportunities.
Pharmaceutical wholesalers act as intermediaries between pharmaceuticalmanufacturers and retailers and facilitate the delivery of the right medicines in a timely, efficient, and secure manner. Wholesale distributors are responsible for guaranteeing product quality and preventing the influx of counterfeited drugs.
ProxsysRx has optimized dozens of 340B programs — generating tens of millions in savings & revenue for the health systems we serve — and the most common question we receive from interested hospitals is, “What’s our 340B network realistically worth?” Why It’s Wrong, And How Hospitals Can Deal With It.
Four years ago, I pivoted in my career, becoming a mechanical design engineer for a Manchester-based Heating, Ventilation and Air Conditioning (HVAC) company – designing air handling units for hospitals, pharmacies, schools and supermarkets. In October 2021, I joined the engineering department at Envair Technology, designing isolators.
Recent cyberattacks on major entities like Sun Pharma, AIIMS, and Safdarjung Hospital underscore a critical vulnerability: inadequate cybersecurity infrastructure. With over 1.9 million attacks in 2022 alone, the urgency for a comprehensive cybersecurity overhaul is evident.
Kirschenbaum — Last week, the United States Court of Appeals for the District of Columbia ruled that Section 340B of the Public Health Service Act does not prohibit pharmaceuticalmanufacturers from imposing conditions on the distribution of discounted drugs to covered entities in the program. In United Therapeutics Corporation v.
What are the top three supply-related challenges facing pharmaceuticalmanufacturers? Yammahi was instrumental in building Hayat’s extensive distribution network needed to supply vaccines during the COVID-19 pandemic.
This led to new commitments and action to expand Africa’s industrial capacity for pharmaceuticalmanufacturing. Five products, eight countries Broadly speaking, USP and RHSC seek to promote healthier markets, including through growth in regional manufacturing of health supplies in SSA.
Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceuticalmanufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.
In recent months, hospitals and other health care facilities have struggled to obtain sufficient stock of even basic supplies , such as saline, and national media outlets have drawn attention to shortages affecting widely prescribed drugs like amoxicillin and mixed amphetamine salts (Adderall®). Prescription medications are not exempt.
Licenses for our DCI reports are regularly purchased by nearly every entity involved in the drug channel: pharmaceuticalmanufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.
Take Charleston, South Carolina, for example, where a growing number of medical device and pharmaceuticalmanufacturers, research laboratories and service companies have sprung up or settled in recent years. In mid-sized Charleston, connections and collaborations are a constant.
” LEVEL TRACKING Pharmaceuticalmanufacturing company Seidenader Vision has also developed a system – the SATrack and Trace. ” THE DOMINO EFFECT There are many examples of how these technologies have helped make pharmaceuticalmanufacturing safer for the consumer.
Suresh Kannan: This latest semi-annual platform update brings innovative revenue optimization and compliance solutions to our high-tech and life sciences customers, including pharmaceuticalmanufacturers. Specifically, our Fall 2022 release helps our pharma customers achieve compliance and meet their strategic objectives quickly.
Here are some of the spheres that currently require outcomes research HEOR experts: PharmaceuticalManufacturers – companies that produce drugs, healthcare products, medical equipment may use HEOR pharma expert’s services. Healthcare Institutions – public or private hospitals, healthcare providers, medical centers.
facility for manufacturing biologics in his presentation. —a combination of AI, IoT, and Digital Twins—for pharmaceuticalmanufacturers. Dr. Samir discussed Agilent's new Agilent University idea as well as how the company is creating analytical solutions to enable the smart manufacture of biologics.
Hospitals and health systems maintain formularies of products that they will stock in the hospital pharmacy and administer to inpatients. For a hospital, it’s a relatively simple question - does this strategy reduce how much money the hospital spends on drugs.
China and India together supply more than 70 percent of APIs used in US drug manufacturing, while Europe remains a key supplier of high-value biologics and specialised medicines. 3 Additionally, tariffs could increase lead times for manufacturing, as companies navigate customs barriers and seek alternative suppliers. References 1.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content